GU Cancers 2019 | The evolving first-line treatment landscape for advanced RCC

The systematic treatment landscape has changed enormously over the past few years for advanced renal cell carcinoma (RCC). Rana McKay, MD, of the University of California San Diego, San Diego, CA, reports that the first-line treatment options for advanced ACC have been increasing significantly since the emergence of checkpoint-inhibitors and VEGF-targeted therapies. This video was recorded at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA.